5-Hydroxytryptamine4 Receptor Activation of the Extracellular Signal-regulated Kinase Pathway Depends on Src Activation but Not on G Protein or β-Arrestin Signaling

Gaël Bartheòt,*†‡§ Bérénice Framery,*†‡§ Florence Gaven,*†‡§ Lucie Pellissier,*†‡§ Eric Reiter,†§# Sylvie Claeyesen,*†‡§ Joël Bockaert,*†‡§ and Aline Dumuis*†‡§

*Institut de Génomique Fonctionnelle, Montpellier F-34094, France; †Centre National de la Recherche Scientifique Unité Mixte de Recherche 5203, Montpellier F-34094, France; ‡Institut National de la Santé et de la Recherche Médicale, U661, Montpellier F-34094, France; §Université Montpellier I, Montpellier F-34094, France; †Université Montpellier II, Montpellier F-34094, France; ¶Institut National de la Recherche Agronomique, Unité Mixte de Recherche 6175, Nouzilly F-37380, France; *Centre National de la Recherche Scientifique, Nouzilly F-37380, France; and @Université Tours, Nouzilly F-37380, France

Submitted December 6, 2006; Revised February 9, 2007; Accepted March 14, 2007
Monitoring Editor: J. Silvio Gutkind

Molecular Biology of the Cell

The 5-hydroxytryptamine4 (5-HT4) receptors have recently emerged as key modulators of learning, memory, and cognitive processes. In neurons, 5-hydroxytryptamine4 receptors (5-HT4 Rs) activate cAMP production and protein kinase A (PKA); however, nothing is known about their ability to activate another key signaling pathway involved in learning and memory: the extracellular signal-regulated kinase (ERK) pathway. Here, we show that 5-HT4R stimulation, in primary neurons, produced a potent but transient activation of the ERK pathway. Surprisingly, this activation was mostly Gs/cAMP/PKA-independent. Similarly, using pharmacological, genetic, and molecular tools, we observed that 5-HT4Rs in human embryonic kidney 293 cells, activated the ERK pathway in a Gs/cAMP/PKA-independent manner. We also demonstrated that other classical G proteins (Gq/11/Gi) and associated downstream messengers were not implicated in the 5-HT4R-activated ERK pathway. The 5-HT4R-mediated ERK activation seemed to be dependent on Src tyrosine kinase and yet totally independent of β-arrestin. Immunocytosfluorescence revealed that ERK activation by 5-HT4R was restrained to the plasma membrane, whereas p-Src colocalized with the receptor and carried on even after endocytosis. This phenomenon may result from a tight interaction between 5-HT4R and p-Src detected by coimmunoprecipitation. Finally, we confirmed that the main route by which 5-HT4Rs activate ERKs in neurons was Src dependent. Thus, in addition to classical cAMP/PKA signaling pathways, 5-HT4Rs may use ERK pathways to control memory process.

INTRODUCTION

Pharmacological, biochemical, and genetic manipulations both in invertebrates (such as Aplysia) and mammals, have provided convincing evidence that 5-hydroxytryptamine (5-HT, serotonin), one of the oldest signaling substances to appear during evolution (Mattson et al., 1988; Michael et al., 1998), is involved in learning and memory (Kandel and Schwartz, 1982). 5-HT also regulates neurogenesis, neurite outgrowth, dendritic spine densities, and long-term synapse reinforcement (Kater et al., 1988; Gaspar et al., 2003; Banasr et al., 2004). Among the 5-HT receptors (5-HTRs) involved in learning and memory, those coupled to Gα are particularly important, because cAMP emerges as a key player in memory events and associated synaptic plasticity events, such as long-term potentiation (LTP) (Siegelbaum and Kandel, 1991). In mammals, the 5-HT4Rs-Gq coupled receptors are important modulators of learning and memory (Bockaert et al., 2004; Kemp and Manahan-Vaughan, 2004, 2005). Nothing is known about their action, in vivo, on another key signaling pathway involved in learning and memory: the extracellular signal-regulated kinase (ERK) pathway (Sweatt, 2004). However, 5-HT4Rs have been demonstrated to activate the ERK pathway in human embryonic kidney 293 (HEK293) cells (Norrn et al., 2003). Our aim was to examine whether this activation also occurs in neurons. Indeed, we observed a 5-HT4R-induced activation of ERKs in neurons in primary culture, but the unexpected finding was that this activation was mostly a protein kinase A (PKA)-independent event.

There are many possible signaling pathways by which a G protein-coupled receptor (GPCR) can activate ERKs. They can be classified in two main pathways. The first pathway
uses a classical G protein activation followed by transduction, via βγ and/or kinases that depend on second messengers (such as PKA, PKC, and phosphatidylinositol 3-kinase [PI3K]), Ras or Rap exchange factors, and finally activation of receptor (epidermal growth factor-receptor [EGF-R]) or nonreceptor (Sρ) tyrosine kinases (Luttrell, 2005). The second pathway does not require G proteins. Indeed, this pathway occurs after G protein uncoupling. β-Arrestins that participate in this uncoupling also mediate endocytosis of the receptor, via clathrin-coated pits. This change of compartment allows the β-arrestin scaffolding of a new signaling complex, where early signaling proteins, such as Sρc, are close to members of the ERK pathway, such as Raf and mitogen-activated protein kinase kinase (MEK) (Leffkowitz and Shenoy, 2005; Wang et al., 2006). Interestingly, the time courses of the G-dependent and the β-arrestin-dependent activation of the ERK pathways are very different. The first activation is transient (a few minutes); the second activation is more persistent (up to 1 hour) and depends on the duration of the receptor endocytosis, which is much longer for class B than for class A receptors (Oakley et al., 2001).

The aim of this study was to explore the signaling events involved in ERK activation by 5-HT4-R, because the PKA pathway, the major signaling cascade of 5-HT4-R, is not implicated in neurons.

We report that 5-HT4-R activates the ERK pathway independently of G protein cascades and β-arrestin but that it requires Sρc tyrosine kinase activation. This pattern of signaling events occurs as well in HEK cells as in neurons.

MATERIALS AND METHODS

Plasmids and Construction of Mutated 5-HT4-R cDNAs

Plasmid pcDNA-3.1-β-arrestin 2-YFP was generously provided by M. Bouvier (University of Montreal, Montreal, Quebec, Canada). Truncated receptor constructs are already described by Claesyn et al. (1999). Briefly, constructs A346 were obtained by inserting a stop codon after residues 346 in the 5-HT4-R cDNA sequence, with the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, California). 5-HT4-D66N and W272A were generated using the same protocol.

Antibodies

Anti-phospho PKA substrates, anti-p44/p42 mitogen-activated protein kinase (MAPK) (ERK1/2), anti-phospho-p44/p42 MAPK (Thr202/Tyr204), anti-phospho-Src Tyr (Tyr416) and anti-Src F-actin are polyclonal antibodies purchased from Cell Signaling Technology (Ozyme, France).

The mouse anti-β2 tag antibody was provided by Dr. S. Costagliola (Institut de Recherche en Biologie Humaine et Nucleaire, Brussels, Belgium) (Adamantidis et al., 1992). The anti-β-arrestin 1 A1CT was a gift from Dr. D. R. Leffkowitz (Duke University Medical Center, Durham, NC). The anti-β-arrestin 2 was purchased from Sigma-Aldrich (St. Louis, MO). Alexa Fluor 488- and Alexa 594-labeled secondary antibodies were purchased from Invitrogen (Cergy-Pontoise, France). The horseradish peroxidase-conjugated anti-rabbit and anti-mouse antibodies were from GE Healthcare (Osay, France).

Small Interfering RNA (siRNA) Transfection

The double-stranded siRNA sequence 5′-ACCUCGGCCUCUCCGGCAUG-3′ was used to simultaneously target human β-arrestin 1 (positions 172–190) and β-arrestin 2 (positions 175–193). Indicated position numbers are relative to the start codon. One small RNA duplex that has no silencing effect was used as a control (5′-AUGGGUCACCUAGAGUACCCG-3′). All the siRNAs were chemically synthesized (Eurogentec, Seraing, Belgium), and they were desiccated and stored at −80°C. All oligonucleotides were validated by high-performance liquid chromatography (HPLC) (Kaye et al., 2006; Kaye et al., 2006). Early passage HEK293 cells at 40% confluence were transfected into six-well plates with 300 ng of plasmid encoding the wt-5-HT4-R. After cell adhesion, siRNAs were transfected at 200 nM by using the Gene Silencer transfection reagent according to the manufacturer’s recommendations (Gene Therapy Systems, San Diego, CA). Briefly, 50 μL of the Gene Silencer transfection reagent was added to 300 μL of minimal essential medium (MEM), whereas RNA mixtures containing 36 μL at 75 μM = 20 μg of RNA, 240 μL of siRNA diluent, and 180 μL of MEM were prepared. Both solutions were allowed to stand 5–10 min at room temperature, and they were mixed by inversion. After a 10- to 20-min incubation at room temperature, the transfection mixture was divided into six equivalent fractions and added to cells into six-well plates containing 750 μL of fresh, serum-free DMEM. After cells were incubated for 4 h at 37°C, an additional 1 mL of DMEM with 20% fetal calf serum (FCS) and 2% penicillin/streptomycin were added to the wells. All assays were performed 3 d after siRNA transfection.

Cell Cultures and Transfection

Primary cultures of colliculi neurons were prepared as described previously (Dumuis et al., 1988). Briefly, cells dissociated from colliculi of 14- to 15-d-old Swiss mouse embryos were plated in serum-free medium in 12-well dishes (5×104 cells/mL; 3 ml/dish). Cultures were maintained 4–5 d at 37°C in a humidified atmosphere in 5% CO2/95% H2Oair and in DMEM/F-12 supplemented with 10% of mix hormone (100 μg/mL transferrin, 25 μg/mL insulin, 60 μM putrescine, 20 μM progesterone, and 30 nM sodium selenite) and antibiotics. HEK293 cells were grown in DMEM supplemented with 10% dialyzed FCS and 1% antibiotics. Owing to the diacylglycerolase activity, cells were transfected by electroporation, as previously described (Claesyn et al., 1999). Colliculi neurons, as well as transfected HEK293 cells, were processed for subsequent experiments, such as immunofluorescence, immunoblotting, or measurement of second messengers (cAMP or inositol phosphates).

Phosphorylation Assays

Cells transfected with the indicated amount of plasmid were plated on six-well dishes and grown for 24 h in DMEM in 10% dialyzed fetal calf serum. Before stimulation, the cells were starved for at least 6 h in serum-free medium. After stimulation, cells were lysed in SDS buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% SDS, proteases inhibitors mixture, and phosphatase inhibitors [1 mM sodium orthovanadate, 10 mM sodium fluoride, and 10 μM leupeptin]). Cell lysates were incubated for 20 min at 4°C and subsequently centrifuged at 12,000 rpm for 10 min at 4°C. For each sample, the amount of proteins was determined by bicinchoninic acid method (Sigma-Aldrich). Four times concentrated Laemmli buffer was added to cell lysates, and samples were separated on a 10% SDS-polyacrylamide gel. The proteins were transferred to nitrocellulose membranes (Hybond-C, Amersham Biosciences) at 18 V until intensity of current stopped decreasing. Membranes were blocked for 1 h at room temperature using Tris-buffered saline blocking solution, containing 5% (wt/vol) milk powder, 0.25% (vol/vol) Tween 20. Membranes were immunoblotted successively with the primary antibodies overnight at 4°C (either 1:1000 anti-p-PAK substrates, anti-p44/p42 (pERK1/2), total anti-p44/p42 (ERK1/2), anti-p-Src Tyr416), or Src F-actin rabbit polyclonal antibody), washed extensively, and incubated with secondary antibodies. After the detection, the membranes were incubated in a Chemiluminescence Reagent Plus kit (PerkinElmer-Cetus, Courtaboeuf, France) and autoradiography, the membranes were stripped with 100 mM glycine, pH 2.2, 0.2% SDS, and 0.1% NP-40 for 30 min at room temperature, rinsed with wash buffer, and immunoblotted as described above as another primary antibody. Autoradiographs were digitized and subsequent analyses were performed with ImageJ (National Institutes of Health, Bethesda, MD) and GraphPad Prism (GraphPad Software, San Diego, CA).

Determination of cAMP Production in Transfected Cells

HEK293 cells were transfected with the appropriate cDNA and seeded into 24-well plates (500,000 cells/well). Twenty-four hours after transfection, a 5-min-stimulation with the appropriate concentrations of 5-HT, 0.1 mM L-aspartic acid, and 0.1 mM L-cysteine. N-Acetylcysteine, a noncompetitive inhibitor of L-cysteine oxidase (Ro-20-1724 was performed for 37°C in 250 μL of HBS (20 mM HEPES, 150 mM NaCl, 4.2 mM KCl, 0.9 mM CaCl2, 0.5 mM MgCl2, 0.1% glucose, and 0.1% bovine serum albumin (BSA)). The same volume of Triton X-100 (0.1%) was added to stop the reaction, and then the cells were incubated 30 min at 37°C. Quantification of cAMP production was performed by homogenous time resolved fluorescence (HTRF) by using the cAMP Dynamic kit (CIS Biointernational, Bagnoles-sur-Ceze, France) according to the manufacturer’s instructions.

Determination of Inositol Production in Transfected Cells

Cells are plated into 24-well dishes (700,000 cells/well). Twenty-four hours after transfection, 50 mM LiCl was added 10 min before a 30-min stimulation with the appropriate concentration of 5-HT and 0.1 mM L-aspartic acid in HEPES buffer saline (HBS). Quantification of inositol phosphates (IP) production was performed by HTRF, using the IP-One assay (CIS Biointernational), according to the manufacturer’s instructions.

Immunofluorescence Microscopy

HEK293 cells expressing tagged wild type (wt) or as346-5-HT4-R with or without yellow fluorescent protein (YFP)-tagged β-arrestin 2 were grown on polymer-foam screens—coated biochip tips with 10% fetal calf serum. Thirty-four hours after transfection, cells were serum-starved overnight. To visualize Rho-tagged receptors, cell surface receptors were labeled with 2 μg/mL antibody for 90 min at 4°C. Cells were then washed with serum-free medium and stimulated with 10 μM 5-HT in the same medium at 37°C. Cells were washed with phosphate-buffered saline, fixed with 4% paraformaldehyde for 20 min at room temperature, and then permeabilized with 0.05% Triton X-100. Cells were then incubated for 1 h at room temperature.
temperature with goat anti-mouse antibody coupled to Alexa Fluor 488 or 594 at 2 μg/ml with or without goat anti-rabbit antibody coupled to Alexa Fluor 594 at 2 μg/ml. After extensive washes, the coverslips were mounted onto slides by using Mowiol mounting media (Hoechst, Frankfurt, Germany). Immunofluorescence microscopy was performed using a Zeiss Axiohot 2 microscope (Carl Zeiss, Jena, Germany) with Zeiss 63× numerical aperture (NA) 1.4 oil immersion lenses. Excitation and emission filters for the different labeled dyes were as follow: YFP and Alexa 488 (green), λex = 450–490 nm, λem = 520 nm; and Alexa Fluor 594 (red), λex = 546 nm, λem = 590 nm.

Coimmunoprecipitation Experiments

HEK293 cells were transfected with wt or Δ346 Rho-tagged 5-HT4R construct as indicated in the figure legends. Cells were seeded at 105/150-mm plate 48 h before the experiment. Briefly, a 5-min stimulation with 10−8 M 5-HT was performed at 37°C in DMEM without serum. Then, the cross-linking reaction was realized during 30 min in Locke’s buffer completed with 1.25 mM of diithiothreitol(succinimidyl propionate) (Pierce Chemical, Perbio-Brebères, France) a membrane-permeable, hydrolysable covalent cross-linker. The cross-link reaction was stopped with Locke 10% FCS. After two washes with Locke’s buffer, cells were incubated in lysis/binding buffer (20 mM HEPES, 150 mM NaCl, 1% NP-40, 10% glycerol, 4 mg/ml dodecylmaltoside, 0.8 mg/ml cholesteryl hemisuccinate, phosphatase, and protease inhibitor). After 30 min of incubation at 4°C, the samples were centrifuged at 15,000 rpm for 15 min. The soluble extract was incubated overnight at 4°C with 20 μl of a mixture 1:1 of protein A/protein G-Sepharose beads (Amersham Pharmacia Biotech) precoupled with 8 μg of anti-Rho-tag antibody. After five washes with homogenization buffer, immunoprecipitated proteins were eluted in Laemmli sample buffer, resolved by SDS-polyacrylamide gel electrophoresis, and detected by Western blotting.

Data Analysis

The dose–response curves were fitted using GraphPad Prism, and the following equation for monophasic dose–response curves:

\[ y = \frac{y_{\text{max}} - y_{\text{em}}}{1 + \left(\frac{[x]}{EC_{50}}\right)^n} + y_{\text{em}} \]

where EC50 is the concentration of the compound necessary to obtain 50% of the maximal effect, and n is the Hill coefficient. All data represented correspond to the mean ± SEM of three independent experiments performed in triplicate. Statistical analysis was carried out with the t test using GraphPad Prism 3.0 software. p values < 0.05 were considered as statistically significant.

RESULTS

Activation of ERK by the Gαi-coupled 5-HT4Rs in Neurons Mostly Takes Place through a cAMP-independent Pathway

In cultured colliculi neurons, endogenous 5-HT4Rs are coupled to the Gαs/cAMP pathway (Dumuis et al., 1988). Indeed, a 2- to 15-min stimulation period with BIMU8 (a selective 5-HT4R agonist) (Bockaert et al., 2004) generated a twofold activation of cAMP production (Figure 1A). BIMU8 also increased the level of p-ERK1/2, and this activation was transient (Figure 1B). Indeed, p-ERK reached a maximal signal after 5-min stimulation and decreased to the basal level after 15 min. This time course of ERK phosphorylation contrasted with those obtained with other GPCRs, such as 2-ARs, vasopressin V2 (V2Rs), or angiotensin II type 1a receptors (AT1AR) (Kim et al., 2005; Ren et al., 2005; Shenoy et al., 2006). In these latter cases, the ERK1/2 activation time courses were divided into two components, a transient G protein-dependent component and a persistent G protein-independent and β-arrestin–dependent component.

Because 5-HT4R–mediated activation of ERK1/2 was transient, we investigated whether this pathway was G protein signaling dependent. We first attempted to evaluate the contribution of the Gαs/cAMP/PKA pathway. To investigate the role of PKA in 5-HT4R-mediated ERK1/2 activation in colliculi neurons, we examined the amount of BIMU8-induced p-ERK1/2 in the presence and absence of 4-cyano-3-methylisoxazolinedione (CMIQ), a selective PKA inhibitor (He and Yeung, 2003). Before this experiment, we determined the concentration of CMIQ necessary to inhibit PKA in neuronal cultures. Immunoblotting with an anti-phospho-PKA substrate revealed that pretreatment of neurons with a concentration of 3 μM CMIQ was sufficient to completely inhibit

Figure 1. Stimulation of 5-HT4Rs coupled to Gαi, in colliculi neurons leads to the activation of ERK, independently of PKA. (A) After 7 d of culture and differentiation, colliculi neurons were incubated in a medium containing 1 nM isobutylmethylxanthine (a phosphodiesterase inhibitor) and 10 μM BIMU8. cAMP accumulation was measured for 2, 5, and 15 min of stimulation at 37°C as indicated in Materials and Methods and expressed as picomoles per well. Results are the mean ± SEM of four independent experiments. *p < 0.01, significantly different from the corresponding cells before BIMU8 treatment. (B) Colliculi neurons were stimulated with 10 μM BIMU8 for the same periods as mentioned in A, and then they were lysed. The phosphorylation state of ERK1/2 of whole cell extract was analyzed by immunoblotting with the antibody to p-ERK1/2. Membranes were then stripped and analyzed with antibody to total ERK. The Western blot shown is representative of five independent experiments. (C) Inhibition of PKA does not lead to the inhibition of p-ERK1/2 in colliculi neurons. Colliculi neurons expressing endogenous 5-HT4R were pretreated with vehicle or 3 μM CMIQ for 30 min before treatment with 10 μM BIMU8 for 5 min. Cell lysates were successively analyzed by immunoblotting with the antibodies to phospho-PKA substrates, to p-ERK1/2, and to total ERK as described in B. The Western blot shown is representative of three independent experiments.
the 5-HT₄R–induced activation of PKA (Figure 1C). We found that BIMU8 still generated ERK1/2 activation in the presence of 3 μM CMIQ with only a slight decrease in p-ERK1/2 signal (Figure 1C).

Our results suggest that activation of 5-HT₄Rs in neurons could induce activation of ERK through a pathway largely independent of PKA. In neurons, a Gₛ-dependent ERK activation can also be excluded, because we detected no IP accumulation after activation of endogenous 5-HT₄Rs (data not shown).

G Protein-independent ERK1/2 Activation by 5-HT₄Rs in HEK293 Cells

In an effort to better understand the molecular mechanisms involved in 5-HT₄R–mediated ERK phosphorylation, we used HEK293 cells transiently transfected with 5-HT₄Rs. We chose HEK293 cells to take advantage of the genetic and molecular tools difficult to set up in primary cultured neurons, such as transfection of cDNA, as well as siRNA. As in colliculi neurons, the time course of 5-HT₄R–induced p-ERK1/2 accumulation observed in HEK293 cells was very transient with a maximum effect after 5 min of stimulation, and the effect returned to the basal level after 10–20 min of stimulation (Figure 2A). The concentration–response curve of the 5-HT₄R ligand-mediated p-ERK1/2 indicated an EC₅₀ of 3 ± 0.2 × 10⁻⁷ M (Figures 2B and 3), a value much higher than the EC₅₀ determined for 5-HT₄R–mediated cAMP accumulation in the same cells (0.9 ± 0.1 × 10⁻⁹ M) (Figure 3).

We then attempted to evaluate how much ERK1/2 activation by 5-HT₄R was dependent on Gₛ, Gₛ, or Gₛ signaling cascades. First, note that in HEK293 cells, 5-HT₄Rs were also able to stimulate IP accumulation with an EC₅₀ for 5-HT slightly higher than its EC₅₀ to stimulate p-ERK accumulation (Figure 3). We generated several 5-HT₄R mutants with different specificities of G protein pathway activation. When the highly conserved aspartate D₆₆ (D².₅₀) in the second transmembrane domain was replaced by an asparagine (N), the receptor was still able to stimulate cAMP production (Figure 3). However, without losing its coupling to Gₛ, this mutant was absolutely unable to stimulate p-ERK1/2 accumulation or stimulate IP accumulation (Figure 3). This was the first initial evidence to prove that the Gₛ/cAMP pathway was not involved in p-ERK1/2 accumulation after 5-HT₄R activation. To exclude the involvement of the Gₛ/inositol-1,4,5-triphosphate pathway, we used the W272A (W₆.₄₈) mutant, which was completely unable to induce an increase in IP accumulation, but it was still able to increase cAMP. Results with both mutants suggest that neither cAMP nor IP was involved in 5-HT₄R–mediated ERK1/2 activation.

To further validate the absence of a role for the Gₛ/cAMP pathway in 5-HT₄Rs–mediated p-ERK1/2 accumulation in HEK293 cells, we examined the effect of 1 mM SQ 22536, an adenylyl cyclase inhibitor. This drug inhibited 5-HT₄R–stimulated cAMP accumulation by >85% (Figure 4B). However, the accumulation of p-ERK1/2 in the presence of 5-HT remained unchanged (Figure 4A). Similarly to the experiment carried out in colliculi neurons, we determined the concentration of CMIQ necessary to inhibit PKA in HEK293 cells lines. We also tested H-89, another PKA inhibitor. Immunoblotting with an anti-phospho-PKA substrate revealed that pretreatment of HEK293 cells with either a concentration of 3 μM CMIQ or 1 μM H-89 was sufficient to completely inhibit the 5-HT₄R–stimulated activation of PKA (Figure 4C). In parallel, we found that 5-HT still generated ERK1/2 activation in the presence of 3 μM CMIQ or 1 μM H-89. Furthermore, we observed that forskolin did not activate ERK1/2 in HEK293 cells (data not shown). This has also been reported by Rey et al. (2006) who concluded that in HEK cells, ERK activation is not responsive to direct stimulation of adenylyl cyclase with forskolin.

To confirm that 5-HT₄R–stimulated ERK1/2 activation did not depend on the Gₛ/IP/phospholipase C (PLC) pathway, we exposed the cells to a PLC inhibitor, U 73122 at 10 μM, and to its inactive analogue U 73434 at 10 μM. Neither of these inhibitors could suppress ERK1/2 activation (Figure 5A); however, U 73122 inhibited ~75% of IP accumulation produced under 5-HT₄R activation (Figure 5B). To independently assess the role of Gₛ; in the activation of ERK1/2, we also determined the effect of pertussis toxin (PTX) preincubation of HEK293 cells expressing the 5-HT₄R β₂-ARs can switch from a Gₛ to a Gₛ coupling and subsequently activate the ERK pathway via βγ. We observed no such event for 5-HT₄Rs. Indeed, a PTX treatment of HEK293 cells had no effect on 5-HT₄R–mediated accumulation of p-ERK1/2 (Fig-
Figure 3. 5-HT-stimulated second messengers (cAMP and IP) and phosphorylation of ERK1/2 in HEK293 cells. Comparison between the effects of 5-HT₄R WT and defective mutants. HEK293 cells transiently expressing either 5-HT₄R WT or mutants (D66N or W272A) were treated with increasing concentrations of 5-HT for cAMP production (5 min), IP production (30 min), and p-ERK1/2 (5 min). Receptor expression levels were similar for all the receptors as revealed by enzyme-linked immunosorbent assay that allowed quantifying relative cell surface receptor expression before agonist stimulation (data not shown). Basal and 5-HT-stimulated cAMP values were 1 ± 0.5 and 9 ± 2 pmol/well, respectively. Basal and 5-HT-stimulated IP values were 0.15 ± 0.5 and 10 ± 3 pmol/well, respectively. For WT, data are expressed as a percentage of the maximum second messenger (cAMP or IP) or p-ERK produced after stimulation with 5-HT 10 μM for 5 min (cAMP and p-ERK) or for 30 min (IP) (top). For mutants, data are expressed as a percentage of the maximum cAMP, IP, or p-ERK1/2 produced by the WT stimulated with 10 μM 5-HT, as indicated above. Analysis of p-ERK1/2 and total ERK content was performed by immunoblotting and quantified by densitometry. The amounts of p-ERK1/2 were always normalized to the total ERK signal obtained by stripping the same immunoblot and determined with the antibody to ERK42/44. Curve fitting was performed with the GraphPad Prism software. For all the curves, the data are the mean ± SEM of at least four independent experiments.

ure 5C). Altogether, the present data indicate that 5-HT-stimulated p-ERK accumulation in cells expressing 5-HT₄R does not require the generation of a classical second messenger that is dependent on G protein (Gₐ, Gᵢ, and Gₖ) signaling.

To exclude that ERK activation could perhaps result from the transactivation of EGF-R as described for some GPCRs in HEK293 cells (Turner et al., 2001; Beom et al., 2004), we tested the effect of AG1478, a selective EGF-R inhibitor, on ERK1/2 activation in response to 5-HT. As shown in Figure 5D, 250 nM tyrphostin/AG1478 does not reduce ERK1/2 activation induced by 5-HT₄R activation, whereas at this concentration EGF-R-mediated ERK activation was inhibited. Moreover, pretreating HEK293 cells with 100 nM wortmannin 30 min before activation of the 5-HT₄R excludes the involvement of PI3 kinase in 5-HT₄R-mediated activation of ERK1/2 (data not shown).

5-HT₄R-induced ERK Phosphorylation Involves Src Kinase

Previous studies have demonstrated that activation of the 5-HT₄Rs present in the enterocyte Caco-2 cell line inhibits apical Cl⁻/OH⁻ exchange activity by activating the non-receptor tyrosine kinase Src (Saksena et al., 2005). Moreover, Src has been shown to play a prominent role in GPCR-induced ERK activation (Luttrell and Luttrell, 2004). In a few situations, Src may be directly activated by binding to the GPCR, although a G protein was involved (β₂-AR and P2Y2 receptors) (Cao et al., 2000; Liu et al., 2004). Src can also be activated after its recruitment by β-arrestin together with members of the ERK cascade such as Raf and MEK during β-arrestin-dependent endocytosis of the receptor (Wang et al., 2006). To determine whether one of these mechanisms was required for 5-HT₄R–induced activation of ERK1/2, we first tested the sensitivity of this activation on the Src-specific tyrosine kinase inhibitor PP2 (Bain et al., 2003). As illustrated in Figure 6A, line 1, pretreating the cells with 10 μM PP2 resulted in a dramatic decrease (> 80%) in p-ERK accumulation. In contrast, 5-HT₄R–dependent ERK1/2 phosphorylation was only slightly reduced by PP3, a structural analogue of PP2 that does not inhibit Src kinase. To further establish the role of Src, we demonstrated that phosphorylation of Src kinase at Tyr 416 was induced by 5-HT₄Rs stimulation, an effect blocked by PP2 but not PP3 (Figure 6A, line 2).

Data in Figure 6B show immunofluorescence detection of Rho-tagged 5-HT₄Rs, p-ERK1/2 as well as p-Src (Tyr 416) in HEK293 cells under basal conditions or after stimulation with 10 μM 5-HT for 5 and 30 min. Under basal conditions, a very low level of p-ERK1/2 was detected, whereas an intense accumulation of p-ERK1/2 was observed after 5-HT stimulation for 5 min. Note that there was a clear colocalization between the receptor and p-ERK1/2 at the submembrane level. p-Src was already detected under basal conditions and stimulation of 5-HT₄Rs for 5 min with 5-HT, further increased p-Src levels. As illustrated in Figure 6B, a colocalization between 5-HT₄Rs and p-Src at the plasma membrane level can be observed. As already described using immunoblotting experiments (Figure 2), the immunofluorescence experiments in Figure 6 further confirmed that a 30-min stimulation with 5-HT was not associated with a persistent accumulation of p-ERK1/2. At 30 min, the receptors could still be detected at the cell surface and also in a perinuclear area, as described previously (Barthet et al., 2004).

Vol. 18, June 2007 1983

5-HT₄ Receptor Mediates ERK Activation
One very interesting observation was that the receptor-induced Src phosphorylation was still present even after a 30-min stimulation with 5-HT (Figure 6B). Note that this p-Src (Tyr 416) pool colocalized with cell surface receptors at 5 min as well as with internalized receptors in perinuclear compartments at 30 min (Figure 6B). Immunoblotting experiments confirmed that the activation of Src after stimulation

![Image](image_url)
overnight. Cells were incubated with antibody against Rho-slip. Twenty-four hours after transfection, cells were serum starved and stimulated with antibody to Src inactive (line 3). (B) Colocalization of p-ERK1/2 and Src with antibody to p-Src (Tyr 416) (line 2), and total Src with Pan antibody-labeled receptors (green channel) and the appearance of p-ERK1/2 with antibody against p-ERK1/2 (line 1), active Src analyzed by immunoblotting. The blots were probed sequentially to detect p-ERK1/2, p-Src (Tyr 416) and to total Src.

Figure 6. 5-HT₄R-mediated ERK1/2 activation depends on Src tyrosine kinase activation. (A) Stimulation of 5-HT₄R activates Src. Inhibition of Src prevents ERK activation. Serum-starved HEK293 cells expressing 5-HT₄R were pretreated with the Src kinase inhibitor PP2 at 10 μM or with the inactive analogue PP3 at 10 μM 30 min before a 5-min stimulation with 10 μM 5-HT. The cell lysates were analyzed by immunoblotting. The blots were probed sequentially to detect p-ERK1/2 with antibody against p-ERK1/2 (line 1), active Src with antibody to p-Src (Tyr 416) (line 2), and total Src with Pan antibody to Src inactive (line 3). (B) Colocalization of p-ERK1/2 and p-Src (Tyr 416) after stimulation of 5-HT₄R WT. HEK293 cells transfected with 500 ng of Rho-tagged 5-HT₄R were seeded onto coverslips. Twenty-four hours after transfection, cells were serum starved overnight. Cells were incubated 90 min with antibody against Rho-tagged 5-HT₄R at 4°C before a 5- or 30-min stimulation with 10 μM 5-HT. After fixation and permeabilization, cells were sequentially incubated with primary antibody against p-ERK1/2 or p-Src (Tyr 416) and with fluorochrome-labeled secondary antibody. Fluorescence microscopy was then used to visualize the distribution of antibody-labeled receptors (green channel) and the appearance of phosphorylated form of ERK (p-ERK1/2) and Src (p-Src) (red channel). with 5-HT, in contrast to the activation of ERK1/2, was persistent up to 30 min (Figure 6C).

The 5-HT₄R-induced Accumulation of p-ERK1/2 Is Not Dependent on β-Arrestin Recruitment

Recently, a very well documented concept proposed that GPCRs can trigger non-G protein-mediated signaling events. These events are generally mediated via the association of GPCRs with GPCR-associated proteins, such as β-arrestin. In particular, the activation of ERK1/2 by scaffolding complexes composed by β-arrestin, Src, and MAPK cascade effectors have already been reported (for review, see Lefkowitz and Shenoy, 2005). The possibility that the G protein-independent, Src-dependent activation of ERK1/2 by 5-HT₄Rs involves β-arrestin was analyzed. The first argument against this possibility was the transient time course of ERK1/2 activation by 5-HT₄R, compared with the generally persistent β-arrestin-mediated activation of ERK1/2. The second counter-argument was that the C-terminal cluster of Ser/Thr, which was necessary for the recruitment of β-arrestin by the 5-HT₄Rs and for their endocytosis after 15 min of stimulation (Barthet et al., 2005), was not required for 5-HT₄Rs-induced accumulation of p-ERKs (Figure 7). We particularly studied the Δ346 mutant that lacks this Ser/Thr cluster (Figure 7A) and showed that a 5-min agonist stimulation period of the truncated Δ346 mutant induced a robust activation of ERK1/2 that was blocked by PP2 (Figure 7A). A larger truncation of the C-terminal domain Δ327 did not modify the receptor’s ability to mediate p-ERK1/2 accumulation, an effect blocked by PP2 (data not shown). We also confirmed that phosphorylation of ERKs by the Δ346 mutant was associated with an increase in p-Src (Tyr 416) (Figure 7B), which colocalized with the receptor at the plasma membrane. However, a short 5-min stimulation provided a way for the native 5-HT₄R WT to recruit β-arrestin 2-YFP and form complexes localized on the plasma membrane (Figure 8A). On the contrary, no complexes could be detected between Δ346 and β-arrestin 2-YFP (Figure 8A). Thus, the Δ346 mutant was unable to recruit β-arrestin, but at the same time, it was still able to activate p-ERK1/2 and p-Src accumulations (Figure 7A). These data exclude a role for β-arrestin in the 5-HT₄R-mediated activation of ERKs.

We then analyzed by coimmunoprecipitation the physical interactions between p-Src and the receptors (WT and Δ346) and between β-arrestins and the same receptors. Immunoprecipitation of Rho-tagged WT and Δ346–5-HT₄Rs resulted in a significant basal communoprecipitation of p-Src that

Immunofluorescence microscopy was performed using a Zeiss Axiohot2 microscope with Zeiss 63× NA 1.4 oil immersion lenses. Representative images from several independent experiments are shown. Top, distribution of Rho-tagged 5-HT₄R before (basal) or after 5- and 30-min addition of 10 μM 5-HT to the culture medium at 37°C. The left column shows the distribution of the receptor and the absence of p-ERK1/2 before activation. An increase in phosphorylation state of ERK1/2 after 5-min treatment with 5-HT. Merged images were magnified to show colocalization of 5-HT₄R with p-ERK1/2 at the plasma membrane after 5-min stimulation. Bottom, phosphorylation state of p-Src (Tyr 416) before and after 5-HT₄R stimulation. Phosphorylation state and colocalization with 5-HT₄R is longer for p-Src than for p-ERK1/2. (C) HEK293 cells were transfected with 5-HT₄R. Twenty-four hours later, the cells were starved in serum-free medium overnight and stimulated with 10 μM 5-HT for the indicated periods at 37°C. Phosphorylated Src (Tyr 416) of all the cell lysates was determined by immunoblotting with the antibody to active p-Src (Tyr 416) and to total Src.
was largely increased after a 5-min stimulation with 5-HT (Figure 8B). The amounts of p-Src coimmunoprecipitated were comparable between the WT and the Δ346 (Figure 8B, line 1). The presence of endogenous β-arrestins coimmunoprecipitated was solely observed after 5 min of stimulation of the WT-5-HT₄R. These data confirm that the C-terminus is not implicated in Src-dependent 5-HT₄R-mediated ERK activation. Topology of the C-terminal domain of 5-HT₄R WT and Δ346 is represented on the left. Putative Ser/Thr phosphate acceptor sites are represented by black circles. HEK293 cells were transfected with 100 ng of Rho-tagged WT and Δ346 5-HT₄R. Serum-starved HEK293 cells expressing the WT and the mutant were pretreated or not with the Src kinase inhibitor PP2 at 10 μM for 30 min before the stimulation with 10 μM 5-HT for 5 min. Whole cell lysates were prepared and analyzed by immunoblotting with antibody to p-ERK1/2. A representative blot of each experiment is shown. Both WT and truncated mutant Δ346 phosphorylate ERK1/2 in the same manner, depending on Src kinase.

(B) Colocalization of p-ERK1/2 and active p-Src after WT and Δ346 stimulation. HEK293 transfected with 500 ng of Rho-tagged 5-HT₄R or Rho-tagged Δ346 were seeded onto coverslips. Twenty-four hours after transfection, cells were serum starved overnight. Cells were incubated 90 min with antibody against Rho-tagged 5-HT₄R at 4°C before a 5- or 30-min stimulation period with 10 μM 5-HT. After fixation and permeabilization, the cells were sequentially incubated with primary antibody against p-ERK1/2 or p-Src (Tyr 416) and with fluorochrome-labeled secondary antibody. Fluorescence microscopy was then used to visualize distribution of antibody-labeled receptors (green channel) and appearance of the phosphorylated form of active ERK1/2 and active Src (red channel). Immunofluorescence microscopy was performed using a Zeiss Axioshot2 microscope with Zeiss 63× NA 1.4 oil immersion lenses. Representative images from several independent experiments are shown. Top, distribution of Rho-tagged 5-HT₄R or Rho-tagged Δ346 before (basal) or after 5-min treatment with 10 μM 5-HT at 37°C. An increase in phosphorylation of p-ERK1/2 is visualized at the plasma membrane after 5-min stimulation with 5-HT of both WT and Δ346. Merged images were magnified to show colocalization of both receptors (WT and Δ346) with p-ERK1/2 at the plasma membrane after 5-HT₄R stimulation. Phosphorylation states of active Src before (basal) and after 5-HT and localization of p-ERK and p-Src do not differ between WT and Δ346 after 5-min stimulation.

Therefore, these results did not completely exclude the possibility that Src and ERK activations by 5-HT₄Rs were dependent on β-arrestins. Thus, we examined the effect of β-arrestin depletion, by RNA interference, on 5-HT₄R-mediated activation of p-ERK. As illustrated in Figure 8C, the depletion of both β-arrestins 1 and 2 (Figure 8C, lines 3 and 4) does not affect the 5-HT₄R-mediated Src and ERK1/2 activation (Figure 8C, lines 1 and 2, respectively). The latter signal remains unaffected, whereas the amounts of β-arrestins 1 and 2 were reduced by >70%. Altogether, these data further confirm that ERK1/2 activation stimulated by 5-HT₄R was not mediated by β-arrestin.

Moreover, neither β-arrestin nor receptor endocytosis were required. Overexpression of the dominant-negative β-arrestin (319–418) (which blocked 5-HT₄R endocytosis; Barathet et al., 2005) as well as inhibition of endocytosis with hypertonic 0.4 M sucrose or with concanavalin A had any effect on 5-HT₄R-mediated ERK stimulation (data not shown). These observations support the immunofluorescent labeling of antibody-labeled receptors (green channel) and appearance of the phosphorylated form of active ERK1/2 and active Src (red channel). Immunofluorescence microscopy was performed using a Zeiss Axioshot2 microscope with Zeiss 63× NA 1.4 oil immersion lenses. Representative images from several independent experiments are shown. Top, distribution of Rho-tagged 5-HT₄R or Rho-tagged Δ346 before (basal) or after 5-min treatment with 10 μM 5-HT at 37°C. An increase in phosphorylation of p-ERK1/2 is visualized at the plasma membrane after 5-min stimulation with 5-HT of both WT and Δ346. Merged images were magnified to show colocalization of both receptors (WT and Δ346) with p-ERK1/2 at the plasma membrane after 5-HT₄R stimulation. Phosphorylation states of active Src before (basal) and after 5-HT and localization of p-ERK and p-Src do not differ between WT and Δ346 after 5-min stimulation.

Figure 7. 5-HT₄R-mediated ERK phosphorylation through Src activation does not involve the C-terminal domain of 5-HT₄R. (A) The C terminus is not implicated in Src-dependent 5-HT₄R-mediated ERK activation. Topology of the C-terminal domain of 5-HT₄R WT and Δ346 is represented on the left. Putative Ser/Thr phosphate acceptor sites are represented by black circles. HEK293 cells were transfected with 100 ng of Rho-tagged WT and Δ346 5-HT₄R. Serum-starved HEK293 cells expressing the WT and the mutant were pretreated or not with the Src kinase inhibitor PP2 at 10 μM for 30 min before the stimulation with 10 μM 5-HT for 5 min. Whole cell lysates were prepared and analyzed by immunoblotting with antibody to p-ERK1/2. A representative blot of each experiment is shown. Both WT and truncated mutant Δ346 phosphorylate ERK1/2 in the same manner, depending on Src kinase. (B) Colocalization of p-ERK1/2 and active p-Src after WT and Δ346 stimulation. HEK293 transfected with 500 ng of Rho-tagged 5-HT₄R or Rho-tagged Δ346 were seeded onto coverslips. Twenty-four hours after transfection, cells were serum starved overnight. Cells were incubated 90 min with antibody against Rho-tagged 5-HT₄R at 4°C before a 5- or 30-min stimulation period with 10 μM 5-HT. After fixation and permeabilization, the cells were sequentially incubated with primary antibody against p-ERK1/2 or p-Src (Tyr 416) and with fluorochrome-labeled secondary antibody. Fluorescence microscopy was then used to visualize distribution of antibody-labeled receptors (green channel) and appearance of the phosphorylated form of active ERK1/2 and active Src (red channel). Immunofluorescence microscopy was performed using a Zeiss Axioshot2 microscope with Zeiss 63× NA 1.4 oil immersion lenses. Representative images from several independent experiments are shown. Top, distribution of Rho-tagged 5-HT₄R or Rho-tagged Δ346 before (basal) or after 5-min treatment with 10 μM 5-HT at 37°C. An increase in phosphorylation of p-ERK1/2 is visualized at the plasma membrane after 5-min stimulation with 5-HT of both WT and Δ346. Merged images were magnified to show colocalization of both receptors (WT and Δ346) with p-ERK1/2 at the plasma membrane after 5-HT₄R stimulation. Phosphorylation states of active Src before (basal) and after 5-HT and localization of p-ERK and p-Src do not differ between WT and Δ346 after 5-min stimulation.
DISCUSSION

The present study provides evidence that 5-HT_{4}R stimulation, which mediates ERK activation, involves activation of the nonreceptor tyrosine kinase Src as a signaling event. If a number of GPCRs can function either independently of their G protein partners, or independently of β-arrestin, 5-HT_{4}R mediated ERK activation is the first example that involves neither a classical Gα protein signaling (G_{αi}/G_{αq}/G_{αi}) and associated messengers, nor β-arrestins. β-Ar and β-AR do not require β-arrestins to induce ERK1/2 activation through a direct interaction with Src kinase, but it does require G_{i} proteins (Cao et al., 2000). V_{2} vasopressin receptors activate a mechanism independently of G protein signaling, by involving Src and β-arrestin (Charest et al., 2007).

In colliculi neurons, 5-HT_{4}R-mediated ERK activation seems to be largely PKA independent, because BIMU8 still generated a strong ERK1/2 activation in the presence of 3 μM CMIQ, a selective PKA inhibitor (Figure 1D). We blotting by using the antibody to p-Src (Tyr 416) (line 1) and the antibody to β-arrestins 1 and 2 (line 2). The presence of the receptor was revealed by using the antibody anti-Rho-tag (line 3). (C) Down-regulation of β-arrestin expression by siRNA does not inhibit ERK phosphorylation mediated by 5-HT_{4}R. Early passage HEK293 were transfected with 5-HT_{4}R and with control or β-arrestin 1- and 2-specific siRNA. Seventy-two hours after transfection, cells were stimulated 5 or 30 min before lysis. p-Src, p-ERK, and β-arrestin contents were analyzed by Western blotting. The same blot was probed and stripped, sequentially, for p-Src (Tyr 416) and p-ERK1/2 (lines 1 and 2) and β-arrestins (lines 3 and 4). A representative illustration of three experiments is shown in A–C.
Figure 9. Src-dependent 5-HT₄R-mediated ERK1/2 activation also occurs in neurons. (A) Colliculi neurons endogenously expressing 5-HT₄R were stimulated with vehicle or BIMU8 (a 5-HT₄R agonist) and pretreated with 250 nM tyrphostin/AG1478 for 30 min.

Total lysates were analyzed by immunoblotting with the indicated antibodies. The same immunoblot was probed sequentially for p-Src with antibody to active p-Src (Tyr 416), for total Src with antibody against full Src, for p-ERK1/2 with the antibody to activate ERK1/2, and for total ERK1/2 with the antibody to ERK42/44. Quantification of p-Src and p-ERK1/2 was performed by densitometric analysis using NIH Image software. Data are means ± SEM of results obtained in four independent experiments. *p < 0.05 versus corresponding values measured in untreated neurons. (B) Colliculi neurons were pretreated with the Src kinase inhibitors PP2 at 10 μM for 30 min before the stimulation with 10 μM BIMU8 or 100 ng/ml EGF for 5 min. Total lysates were analyzed by immunoblotting with antibody to p-ERK1/2. (C) 5-HT₁₃R-mediated ERK activation does not require transactivation of EGF-R tyrosine kinase. Colliculi neurons were pretreated with 250 nM tyrphostin/AG1478 for 30 min before stimulation with 10 μM BIMU8 or 10 ng/ml EGF during 5 min. Total lysates were analyzed by immunoblotting with antibody to p-ERK1/2. (D) 5-HT₄R-mediated ERK activation does not require Src kinase inhibitors PP2 at 10 μM for 30 min before stimulation with 5-HT₄R agonists, 20 μM H-89 inhibited 5-HT₁₃R-induced ERK1/2 activation (Norum et al., 2003). The reasons for this discrepancy are not known. One possible explanation could be that at 20 μM H-89 loses its specificity and inhibits other kinases in addition to PKA. Indeed, a previous report mentions that from 10 μM, H-89 inhibited many kinases even stronger than PKA (Davies et al., 2000).

Based on these observations, we can postulate that the Gₛ/cAMP/PKA pathway and activation of ERK1/2 could be two independent 5-HT₁₃R-mediated signaling both in neurons and HEK293 cells. It is interesting to note that Dyer et al. (2003) demonstrated that 5-HT₄R-mediated ERK activation in Aplysia sensory neurons was not dependent on cAMP. These data do not indicate that cAMP is not able to stimulate ERK activation in neurons but only that activation of ERK by 5-HT₄Rs is mostly cAMP/PKA independent. Indeed, activation of ERKs via a cAMP route is known to occur in several cells, such as primary neurons in culture (Vincent et al., 1998), PC12 cells, melanocytes, and thyroid cells, and it generally occurs via a B-Raf–MEK pathway (Dumaz and Marais, 2005). In contrast, in many other cells, cAMP inhibits ERK via inhibition of C-Raf, which leads to the well-known antiproliferate effects of cAMP (Dumaz and Marais, 2005).

We have used several pharmacological and genetic tools to obtain further arguments to exclude the Gₛ/cAMP/PKA pathway in HEK293 cells. SQ 22536, a potent inhibitor of the adenylyl cyclase, suppresses 5-HT₁₃R–induced cAMP production without suppressing 5-HT₁₃R–induced ERK activation. Finally, the D66N receptor mutants that stimulate cAMP production are unable to activate the ERK1/2 pathway. We also exclude any implication of the Gₛ/PLC pathway. For unknown reasons, 5-HT₁₃Rs activate the production of IP in HEK293 cells but not in neurons (our unpublished data). Thus, we looked for a possible role of the Gₛ/PLC pathway in 5-HT₁₃R–induced ERK activation in HEK293 cells. The role of PLC activation was excluded by showing that U 73122, an inhibitor of PLC, but not its inactive analogue, does not suppress the effect of 5-HT₁₃Rs on p-ERK1/2, whereas it decreases their ability to activate IP production ~75%. In addition, the W272A (W6.48) receptor mutants do not activate IP production, but they stimulate ERK activation. Finally, we eliminated a contribution of Gₛ by pretreating cells with PTX. Indeed, a switch from Gₛ to Gi can occur for Gₛ-coupled receptors, as demonstrated for β₂-AR. In this latter case, the switch to Gi after Gₛ activation allows a subsequent stimulation of Gi and the release of βγ subunits that causes ERK activation (Daaka et al., 1997). Our data also eliminate the PI3K pathway and transactivation of EGF receptor tyrosine kinases as contributors to 5-HT₄R–mediated ERK activation.
It was surprising to find that classical G protein signaling pathways are not implicated in 5-HT$_4$R-mediated ERK activation. Indeed, the rapid and transient time course of this activation was similar to the G protein-dependent components of ERK activation by other GPCRs, such as AT1AR, V$_2$R and also $\beta_2$-AR (Shenoy et al., 2006). The classical paradigm that relates the strong but transient increase of the p-ERK1/2 signal to the G protein-dependent pathway (Lefkowitz and Shenoy, 2005) seems to present some exceptions.

Indeed, 5-HT$_4$R stimulation of p-ERK is totally dependent of Src activation. Moreover, the concentration–response curve of the 5-HT$_4$R ligand-mediated p-ERK indicated that only high concentrations of agonist contributed to p-ERK phosphorylation ($>10^{-7}$ M). No p-ERK signal was observed before administering $10^{-7}$ M 5-HT$_4$R agonist, whereas cAMP formation was maximal at $10^{-8}$ M 5-HT. Our observations are consistent with those by Sun et al. (2007) who recently reported that $\beta_2$-AR G protein-coupled signaling needs low concentrations of isoproterenol, whereas $\beta_2$-AR non-G protein signaling needs high concentrations of this agonist (Sun et al., 2007). Why do G protein/cAMP- and Src-dependent signaling pathways require such different agonist concentrations when they involve the same 5-HT$_4$R? One likely explanation is that the receptor can adopt two different activated (R*) conformations. One conformation is stabilized by low 5-HT concentrations (activating the Gs pathway), and the other conformation is stabilized by high 5-HT concentrations (activating the Src signaling pathway). In this regard, we have already provided evidence for the occurrence of multiple and well-defined conformational states of the 5-HT$_4$R, depending on the ligand (Baneres et al., 2005).

Previous observations demonstrate that activation of 5-HT$_4$Rs in the enterocyte cell line Caco2 inhibits apical Cl$^-$/OH$^-$ exchange activity, via activation of the nonreceptor tyrosine kinase Src (Saksema et al., 2005). This result does not seem to be cell specific, because we demonstrated that 5-HT$_4$Rs also stimulated Src activation, both in epithelial HEK293 cell lines and in neurons in primary culture. In these cells, activation of Src was required to activate the ERK1/2 pathway by 5-HT$_4$Rs.

By immunoblotting and immunofluorescence staining, we observed that the ERK1/2 activation by 5-HT$_4$Rs was very transient. In contrast, the activation of Src was more persistent and still present at 30 min. Active Src remained associated with the internalized receptor and was accumulated in a perinuclear compartment. Moreover, upon stimulation, 5-HT$_4$Rs coimmunoprecipitated with p-Src. Further work is needed to determine the putative cellular role, if any, of this endocytosed receptor–p-Src complex.

One of the key questions was to know how did 5-HT$_4$Rs mediate Src activation. Do 5-HT$_4$Rs recruit Src kinase directly, or do they require $\beta$-arrestin recruitment, as shown for some GPCRs (Lefkowitz and Shenoy, 2005)? We used many approaches to demonstrate that $\beta$-arrestin recruitment was not necessary to observe a 5-HT$_4$R-mediated phosphorylation of both ERK and Src. First, the time course of 5-HT$_4$-induced ERK activation (Figures 1B and 2A) did not support the involvement of $\beta$-arrestin in the 5-HT$_4$R-induced p-ERK1/2 accumulation. Indeed, the $\beta$-arrestin–dependent activation of ERK1/2 by GPCRs was associated with receptor endocytosis and was generally slow and persistent (Shenoy et al., 2006), whereas the 5-HT$_4$R activation of ERK1/2 was very rapid and transient. Second, the absence of involvement of $\beta$-arrestin in this pathway was also supported by our previous and present reports demonstrating that the Δ346 mutant, devoid of the C-terminal tail cluster of serine/threonine, failed to bind to $\beta$-arrestin, but it was able to stimulate ERK1/2 in a Src-dependent manner, like native 5-HT$_4$Rs. Third, the depletion by RNA interference of $\beta$-arrestins 1 and 2 did not modify the ability of 5-HT$_4$Rs to induce ERK1/2 and Src phosphorylations. All these data clearly confirm that ERK activation stimulated by 5-HT$_4$R was not mediated by $\beta$-arrestin. This was an unexpected finding, because 5-HT$_4$Rs belong to class B type, and they have been shown to be stably associated with $\beta$-arrestin without recycling or degradation over a long period (Barthet et al., 2005).

Arrestin seems to be an absolute requirement for ERK activation by some GPCRs, including $\alpha_2$-ARs (Wang et al., 2004), gonadotropin-releasing hormone receptors (Benard et al., 2001), and the D2 and D3 dopamine receptors (Beom et al., 2004). However, 5-HT$_4$Rs seem to be the only GPCRs that activate ERK1/2 in a G protein-signaling-independent and $\beta$-arrestin–independent pathway. Note also that 5-HT$_4$R–mediated ERK1/2 activation was also independent of receptor endocytosis, as already demonstrated for the $\alpha_2$-AR (Wang et al., 2004). To date, we have not been able to determine whether Src and p-Src interact directly or indirectly via other unknown scaffolding proteins to 5-HT$_4$Rs. The absence of a PXXP sequence in 5-HT$_4$R sequences excludes the possibility that the receptors bind to the Src homology 3 (SH3) domain. In contrast, there are several Tyr residues within the cytoplasmic domains of the 5-HT$_4$Rs (loops i$_2$, i$_3$) and carboxy terminal (C-t) that are all putative SH2-binding sites after phosphorylation. The different C-t truncated 5-HT$_4$Rs (Δ327 and Δ346) were still able to activate the ERK cascade through Src. This indicates that the Tyr residues of C-t were not implicated in Src recruitment. This is in contrast with what has been reported for the $\beta_2$-AR. Indeed, Fan et al. (2001) demonstrated that phospho-Tyr 350 in the C-t of $\beta_2$-AR is important for Src binding. However, in contrast to our data, Src binds the $\beta_2$-AR to mediate agonist-induced receptor desensitization but not to mediate ERK activation (Fan et al., 2001). We have generated several mutants in which, Tyr was substituted by Phe (Tyr 119, Tyr 129, Tyr 212, and Tyr 216) present in i$_2$ and i$_3$ loops. Unfortunately, all the mutants could still recruit p-Src and stimulate ERK1/2, in a pathway sensitive to PP2 (data not shown). Therefore, it is possible that either an intermediary protein is necessary for the 5-HT$_4$R–pSrc association or that a conformational epitope of the receptor is needed for p-Src recruitment.

The ERK1/2 signaling pathway is critical for multiple cellular processes that include proliferation, differentiation, survival, and migration. Kinetics and subcellular compartmentalization of p-ERKs are the major factors determining which cellular responses are triggered by active ERK signaling (Caunt et al., 2006). In our study, we clearly observed a plasma membrane-restricted ERK activation by immunofluorescence (Figures 6B and 7B). These data are similar to previous findings by Scott et al. (2006) demonstrating a role of activated ERK1/2 at the plasma membrane. In this compartment, p-ERK seems to be implicated in membrane ruffling and cell migration in Hep2 epithelial cells. In neurons, ERK activated at the plasma membrane level could participate in morphological modifications involved in neuroplasticity: neurite outgrowth, dendritic spine maturation, or synapse formation. The finding that 5-HT$_4$Rs activate ERK in neurons sheds light on the capacity of 5-HT$_4$R agonists to improve recognition memory, spatial learning, and cognition (Marchetti et al., 2000, 2004; Micale et al., 2006). Moreover, this signaling pathway could participate in a 5-HT$_4$R–
generated shift from long-term depression to LTP in the hippocampal CA1 region, a process that supports memory formation (Kemp and Manahan-Vaughan, 2004, 2005).

Our data highlight an emerging role for 5-HT4Rs in mediating ERK activation that could be important in learning and memory. We propose that the link between 5-HT4Rs and memory could involve both the cAMP/PKA and the Src/ERK signalling pathways. Nonetheless, a direct relationship between 5-HT4R-mediated ERK activation and memory processing requires further investigation.

ACKNOWLEDGMENTS

We are grateful to Leigh-Anne Swayne for constructive discussion and critical reading of the manuscript and to Angie Turner-Madefor for help in language revision. We thank the Pharmacological screening platform of the Federal Institute of Research (IFR3) for the use of its facilities. This work was supported by grants from the Centre National de la Recherche Scientifique, the Génopole de Montpellier–Languedoc-Roussillon, Pfizer Japan, and the European Community’s Sixth Framework Program (grant LSHB-CT-2003-503337). Gaël Barthet was supported by grants from the Fondation pour la Recherche Medicale.

REFERENCES


